BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2144 related articles for article (PubMed ID: 28076709)

  • 1. Phase 3 Trial of
    Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
    N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
    Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Lutetium [
    Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
    J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
    JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with
    Strosberg J; Kunz PL; Hendifar A; Yao J; Bushnell D; Kulke MH; Baum RP; Caplin M; Ruszniewski P; Delpassand E; Hobday T; Verslype C; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Paganelli G; Severi S; Morse M; Metz DC; Ansquer C; Courbon F; Al-Nahhas A; Baudin E; Giammarile F; Taïeb D; Mittra E; Wolin E; O'Dorisio TM; Lebtahi R; Deroose CM; Grana CM; Bodei L; Öberg K; Polack BD; He B; Mariani MF; Gericke G; Santoro P; Erion JL; Ravasi L; Krenning E;
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2372-2382. PubMed ID: 32123969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Efficacy, Survival, and Safety of [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
    Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety of
    Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
    J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With
    Strosberg J; Wolin E; Chasen B; Kulke M; Bushnell D; Caplin M; Baum RP; Kunz P; Hobday T; Hendifar A; Oberg K; Sierra ML; Thevenet T; Margalet I; Ruszniewski P; Krenning E;
    J Clin Oncol; 2018 Sep; 36(25):2578-2584. PubMed ID: 29878866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):8-9. PubMed ID: 27168104
    [No Abstract]   [Full Text] [Related]  

  • 13. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Retreatment with
    Delpassand ES; Yazdi SM; Ghantoji S; Nakasato A; Strickland C; Nunez R; Shafie A; Cork S; Byrne C; Tang J; Patel J
    J Nucl Med; 2024 May; 65(5):746-752. PubMed ID: 38514088
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Das S; Al-Toubah T; El-Haddad G; Strosberg J
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
    [No Abstract]   [Full Text] [Related]  

  • 18. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of
    Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM
    Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716
    [No Abstract]   [Full Text] [Related]  

  • 20. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 108.